Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

Xiaojuan Yang, Jiuxia Pang, Na Shen, Fei Yan, Lai Chu Wu, Aref Al-Kali, Mark R Litzow, Yong Peng, Robert J. Lee, Shujun Liu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The abundance of the BCR/ABL protein critically contributes to CML pathogenesis and drug resistance. However, understanding of molecular mechanisms underlying BCR/ABL gene regulation remains incomplete. While BCR/ABL kinase inhibitors have shown unprecedented efficacy in the clinic, most patients relapse. In this study, we demonstrated that the Sp1 oncogene functions as a positive regulator for BCR/ABL expression. Inactivation of Sp1 by genetic and pharmacological approaches abrogated BCR/ABL expression, leading to suppression of BCR/ABL kinase signaling and CML cell proliferation. Because of potential adverse side effects of bortezomib (BORT) in imatinib-refractory CML patients, we designed a transferrin (Tf)-targeted liposomal formulation (Tf-L-BORT) for BORT delivery. Cellular uptake assays showed that BORT was efficiently delivered into K562 cells, with the highest efficacy obtained in Tftargeted group. After administered into mice, L-BORT exhibited slower clearance with less toxicity compared to free BORT. Furthermore, L-BORT exposure significantly blocked BCR/ABL kinase activities and sensitized CML cell lines, tumor cells and doxorubicin (DOX) resistant cells to DOX. This occurred through the more pronounced inhibition of BCR/ABL activity by L-BORT and DOX. Collectively, these findings highlight the therapeutic relevance of disrupting BCR/ABL protein expression and strongly support the utilization of L-BORT alone or in combination with DOX to treat CML patients with overexpressing BCR/ABL.

Original languageEnglish (US)
Pages (from-to)36382-36394
Number of pages13
JournalOncotarget
Volume7
Issue number24
DOIs
StatePublished - 2016

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Doxorubicin
Phosphotransferases
Transferrin
Tumor Cell Line
Bortezomib
K562 Cells
Oncogenes
Drug Resistance
Proteins
Cell Proliferation
Pharmacology
Recurrence

Keywords

  • BCR/ABL
  • Bortezomib
  • Chronic myeloid leukemia
  • Liposome
  • Nanoparticle

ASJC Scopus subject areas

  • Oncology

Cite this

Yang, X., Pang, J., Shen, N., Yan, F., Wu, L. C., Al-Kali, A., ... Liu, S. (2016). Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. Oncotarget, 7(24), 36382-36394. https://doi.org/10.18632/oncotarget.8871

Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. / Yang, Xiaojuan; Pang, Jiuxia; Shen, Na; Yan, Fei; Wu, Lai Chu; Al-Kali, Aref; Litzow, Mark R; Peng, Yong; Lee, Robert J.; Liu, Shujun.

In: Oncotarget, Vol. 7, No. 24, 2016, p. 36382-36394.

Research output: Contribution to journalArticle

Yang, X, Pang, J, Shen, N, Yan, F, Wu, LC, Al-Kali, A, Litzow, MR, Peng, Y, Lee, RJ & Liu, S 2016, 'Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis', Oncotarget, vol. 7, no. 24, pp. 36382-36394. https://doi.org/10.18632/oncotarget.8871
Yang, Xiaojuan ; Pang, Jiuxia ; Shen, Na ; Yan, Fei ; Wu, Lai Chu ; Al-Kali, Aref ; Litzow, Mark R ; Peng, Yong ; Lee, Robert J. ; Liu, Shujun. / Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. In: Oncotarget. 2016 ; Vol. 7, No. 24. pp. 36382-36394.
@article{2841b13ba3b94a4987406b49a4db3292,
title = "Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis",
abstract = "The abundance of the BCR/ABL protein critically contributes to CML pathogenesis and drug resistance. However, understanding of molecular mechanisms underlying BCR/ABL gene regulation remains incomplete. While BCR/ABL kinase inhibitors have shown unprecedented efficacy in the clinic, most patients relapse. In this study, we demonstrated that the Sp1 oncogene functions as a positive regulator for BCR/ABL expression. Inactivation of Sp1 by genetic and pharmacological approaches abrogated BCR/ABL expression, leading to suppression of BCR/ABL kinase signaling and CML cell proliferation. Because of potential adverse side effects of bortezomib (BORT) in imatinib-refractory CML patients, we designed a transferrin (Tf)-targeted liposomal formulation (Tf-L-BORT) for BORT delivery. Cellular uptake assays showed that BORT was efficiently delivered into K562 cells, with the highest efficacy obtained in Tftargeted group. After administered into mice, L-BORT exhibited slower clearance with less toxicity compared to free BORT. Furthermore, L-BORT exposure significantly blocked BCR/ABL kinase activities and sensitized CML cell lines, tumor cells and doxorubicin (DOX) resistant cells to DOX. This occurred through the more pronounced inhibition of BCR/ABL activity by L-BORT and DOX. Collectively, these findings highlight the therapeutic relevance of disrupting BCR/ABL protein expression and strongly support the utilization of L-BORT alone or in combination with DOX to treat CML patients with overexpressing BCR/ABL.",
keywords = "BCR/ABL, Bortezomib, Chronic myeloid leukemia, Liposome, Nanoparticle",
author = "Xiaojuan Yang and Jiuxia Pang and Na Shen and Fei Yan and Wu, {Lai Chu} and Aref Al-Kali and Litzow, {Mark R} and Yong Peng and Lee, {Robert J.} and Shujun Liu",
year = "2016",
doi = "10.18632/oncotarget.8871",
language = "English (US)",
volume = "7",
pages = "36382--36394",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "24",

}

TY - JOUR

T1 - Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

AU - Yang, Xiaojuan

AU - Pang, Jiuxia

AU - Shen, Na

AU - Yan, Fei

AU - Wu, Lai Chu

AU - Al-Kali, Aref

AU - Litzow, Mark R

AU - Peng, Yong

AU - Lee, Robert J.

AU - Liu, Shujun

PY - 2016

Y1 - 2016

N2 - The abundance of the BCR/ABL protein critically contributes to CML pathogenesis and drug resistance. However, understanding of molecular mechanisms underlying BCR/ABL gene regulation remains incomplete. While BCR/ABL kinase inhibitors have shown unprecedented efficacy in the clinic, most patients relapse. In this study, we demonstrated that the Sp1 oncogene functions as a positive regulator for BCR/ABL expression. Inactivation of Sp1 by genetic and pharmacological approaches abrogated BCR/ABL expression, leading to suppression of BCR/ABL kinase signaling and CML cell proliferation. Because of potential adverse side effects of bortezomib (BORT) in imatinib-refractory CML patients, we designed a transferrin (Tf)-targeted liposomal formulation (Tf-L-BORT) for BORT delivery. Cellular uptake assays showed that BORT was efficiently delivered into K562 cells, with the highest efficacy obtained in Tftargeted group. After administered into mice, L-BORT exhibited slower clearance with less toxicity compared to free BORT. Furthermore, L-BORT exposure significantly blocked BCR/ABL kinase activities and sensitized CML cell lines, tumor cells and doxorubicin (DOX) resistant cells to DOX. This occurred through the more pronounced inhibition of BCR/ABL activity by L-BORT and DOX. Collectively, these findings highlight the therapeutic relevance of disrupting BCR/ABL protein expression and strongly support the utilization of L-BORT alone or in combination with DOX to treat CML patients with overexpressing BCR/ABL.

AB - The abundance of the BCR/ABL protein critically contributes to CML pathogenesis and drug resistance. However, understanding of molecular mechanisms underlying BCR/ABL gene regulation remains incomplete. While BCR/ABL kinase inhibitors have shown unprecedented efficacy in the clinic, most patients relapse. In this study, we demonstrated that the Sp1 oncogene functions as a positive regulator for BCR/ABL expression. Inactivation of Sp1 by genetic and pharmacological approaches abrogated BCR/ABL expression, leading to suppression of BCR/ABL kinase signaling and CML cell proliferation. Because of potential adverse side effects of bortezomib (BORT) in imatinib-refractory CML patients, we designed a transferrin (Tf)-targeted liposomal formulation (Tf-L-BORT) for BORT delivery. Cellular uptake assays showed that BORT was efficiently delivered into K562 cells, with the highest efficacy obtained in Tftargeted group. After administered into mice, L-BORT exhibited slower clearance with less toxicity compared to free BORT. Furthermore, L-BORT exposure significantly blocked BCR/ABL kinase activities and sensitized CML cell lines, tumor cells and doxorubicin (DOX) resistant cells to DOX. This occurred through the more pronounced inhibition of BCR/ABL activity by L-BORT and DOX. Collectively, these findings highlight the therapeutic relevance of disrupting BCR/ABL protein expression and strongly support the utilization of L-BORT alone or in combination with DOX to treat CML patients with overexpressing BCR/ABL.

KW - BCR/ABL

KW - Bortezomib

KW - Chronic myeloid leukemia

KW - Liposome

KW - Nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=84978153974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978153974&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8871

DO - 10.18632/oncotarget.8871

M3 - Article

C2 - 27144331

AN - SCOPUS:84978153974

VL - 7

SP - 36382

EP - 36394

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 24

ER -